Related Experiment Videos
Allergen-Specific Immunotherapy for Respiratory Allergy in Children: Unmet Needs and Future Goals
Pasquale Comberiati1, Gian Luigi Marseglia2, Salvatore Barberi3
1Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Pediatric Clinic, University of Verona, Verona, Italy.
Insights
Allergen-specific immunotherapy shows efficacy in children with respiratory allergies. Further research is needed on treatment regimens, duration, biomarkers, and preventive effects for better pediatric recommendations.
Area of Science:
- Pediatric Allergy and Immunology
- Immunotherapy Research
Background:
- Allergen-specific immunotherapy (ASIT) is effective for pediatric respiratory allergies.
- Current ASIT use in children faces challenges like optimal administration and treatment duration.
Purpose of the Study:
- To critically review current evidence on ASIT in pediatric populations.
- To identify unmet needs and knowledge gaps in pediatric ASIT.
- To discuss key issues including allergen standardization, study heterogeneity, and regulatory aspects.
Main Methods:
- Critical appraisal of existing literature on pediatric allergen-specific immunotherapy.
- Focus on clinical studies, allergen standardization, and regulatory/pharmacoeconomic factors.
Main Results:
- Evidence supports ASIT efficacy in children for specific products.
- Significant knowledge gaps persist regarding administration, duration, biomarkers, and prevention.
- Heterogeneity in clinical studies and standardization issues complicate recommendations.
Conclusions:
- ASIT is a viable treatment for pediatric respiratory allergies.
- Addressing knowledge gaps is crucial for definitive clinical guidelines.
- Further research on standardization, study design, and economic factors is warranted.
Abstract:
Allergen-specific immunotherapy for the treatment of respiratory allergy is currently supported, at least for selected products, by evidence of efficacy and effectiveness in the pediatric age. However, unmet needs remain in terms of administration regimens, duration of treatment, biomarkers, and preventive effects. These knowledge gaps need to be urgently addressed to provide pediatricians and pediatric allergists with more definite recommendations for the use of this treatment in children. This article critically appraises the most relevant debated issues on allergen-specific immunotherapy in children, focusing on allergen standardization procedures, heterogeneity of clinical studies, and regulatory and pharmacoeconomic aspects.